Increased levels of angiopoietin-2 and tumor necrosis factor α were observed. Early detection of these markers can assist in the clinical diagnosis and guide the appropriate use of antibiotics.

P4, N=100, Not yet recruiting, University of Colorado, Denver | Initiation date: Mar 2024 --> Aug 2024

Our studies show that the NRASQ61R mutation in endothelial cells induces Ang-2 expression in vitro and in vivo. In cultured human endothelial cells, NRASQ61R drives elevated Ang-2 through MAP kinase and mTOR-dependent signaling pathways.

In women, angiopoietin-2 was associated with PWV (β = 0.18). The selected GFs were closely related to atherosclerosis in patients with RA and are potential predictors of CV disease in patients with RA.

P1, N=48, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Nov 2024

P2, N=150, Active, not recruiting, Greater Houston Retina Research | Recruiting --> Active, not recruiting

P1, N=45, Recruiting, Boehringer Ingelheim | Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2024 --> Apr 2025

P1, N=47, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

P1, N=60, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P3, N=280, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting

P=N/A, N=100, Not yet recruiting, Nantes University Hospital

P=N/A, N=13, Completed, Rigshospitalet, Denmark

P3, N=600, Recruiting, Jaeb Center for Health Research | Not yet recruiting --> Recruiting

Data suggest a causal link between cytokines (risk factor), lung damage (mediator), and COVID-19 outcomes.

Inhibitors targeting ANG-2 (Trebananib) and the VEGF (Bevacizumab) effectively blocked the migration ability of spheroids that had been stimulated with rh-ANG-2 and rh-VEGF. Overall, our findings highlight the critical role played by ANG-2 and the VEGF in enhancing the ability of HCC- and iCCA-derived spheroids to migrate and invade, which are key processes in cancer progression.

P4, N=70, Active, not recruiting, Medical University of Graz | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Oct 2024

At the EOT24W, serum Ang-2 level predicts the likelihood of developing HCC following SVR to DAA therapy.

P4, N=100, Not yet recruiting, University of Colorado, Denver

P4, N=446, Recruiting, McMaster University

P3, N=600, Recruiting, Jaeb Center for Health Research | Not yet recruiting --> Recruiting

P3, N=280, Not yet recruiting, Hoffmann-La Roche

The Ang/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.

P=N/A, N=46, Completed, Rigshospitalet, Denmark | Active, not recruiting --> Completed

P2, N=99, Completed, Hoffmann-La Roche | Phase classification: P2b --> P2

P1, N=45, Recruiting, Boehringer Ingelheim | N=150 --> 45

P1/2, N=43, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed

P=N/A, N=58, Active, not recruiting, Rigshospitalet, Denmark

5α-Hydroxycostic acid can inhibit choroidal neovascularization by interfering with the VEGF- and Ang2/Tie2-related pathways, and it may be a good candidate drug for treating CNV.

P1, N=24, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023

P3, N=1479, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

These changes were accompanied by reduced plasma leakage and improved vascular integrity in metastases. Together, these findings suggest that ANGPT2 blockade may be an effective strategy for promoting T cell infiltration and immunostimulatory reprogramming to reduce the growth of liver metastases in PanNETs.

The cut-off level of ANG-2 was set at 3120.68 pg/mL with a sensitivity of 72.04% and a specificity of 93.94% (AUC = 0.87, p < 0.000001). (4) Conlusion: It was concluded that all the proteins studied could be potential diagnostic markers in endometrial cancer.

The DCE-MRI-based radiomics model has the potential to predict Ang-2 expression in HCC patients; the combined model integrating the radiomics score with CR factors can further improve the prediction performance.

In vivo mouse models further highlighted the pro-metastatic role of circFAM169A in CRC. More importantly, we discovered that circFAM169A enhances the expression of angiopoietin-2 by binding to miR-518a-5p.

When compared with bevacizumab, BI 836880 appeared to show at least comparable activity as bevacizumab in terms of its anti-proliferative and anti-angiogenic effects. This study showed that BI 836880 has anti-proliferative, anti-angiogenic and possibly immunomodulatory effect in clinical models of NPC, therefore the dual targeting of VEGF and Ang2 signaling in NPC should be further investigated.

An evaluation of Ang-2 expression and LVD can be used to predict the risk of tumor lymphatic metastasis and determine the prognosis of CMM. These results may also provide a new clinical treatment strategy for CMM.

Upregulated Ang2 levels in blood plasma and cancer tissues of liver cancer patients confirm that Ang2 plays a vital role in the pathogenesis of liver cancer. ANGPT2 rs2442588 and rs11137037 are associated with liver cancer risk, thereby highlighting their role in screening individuals susceptible to liver cancer.

Therapeutic response after ANGPT2 blockade, driven by improved CD8+ T cell infiltration to the tumor core, coincided with spatial TIE2 signaling activation and increased vascular integrity at the tumor periphery where endothelial expression of adhesion molecules was reduced. These data highlight ANGPT2/TIE2 signaling as a key mediator of T cell exclusion and a promising target to potentiate immune checkpoint blockade efficacy in melanoma.

The potential benefit of combined inhibition of Ang-2 and VEGF-A in previously untreated patients with mCRC was evaluated in the phase II McCAVE study (NCT02141295), assessing vanucizumab versus bevacizumab (VEGF-A inhibitor), both in combination with mFOLFOX-6 (modified folinic acid [leucovorin], fluorouracil and oxaliplatin) chemotherapy. These data suggest that Ang-2 may be both a prognostic biomarker in mCRC and a predictive biomarker for vanucizumab in KRAS wild-type mCRC. Thus, this evidence can potentially support the establishment of more tailored treatment approaches for patients with mCRC.

MTD was not reached. BI 836880 alone and in combination with ezabenlimab had a manageable safety profile with preliminary clinical activity in Japanese patients with advanced solid tumors.

P3, N=600, Not yet recruiting, Jaeb Center for Health Research

P1, N=60, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Feb 2023 --> Feb 2024